...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time.
【24h】

Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time.

机译:盐酸芦丁,阿加曲班和美拉加群的影响以及苯普鲁蒙对依卡琳凝血时间的影响。

获取原文
获取原文并翻译 | 示例

摘要

INTRODUCTION: Direct thrombin inhibitors (DTI) prolong the ecarin clotting time (ECT). Oral anticoagulants (OA) decrease prothrombin levels and thus interact with actions of DTIs on the ECT method during concomitant therapy. MATERIALS AND METHODS: Actions of lepirudin, argatroban and melagatran on ECT were investigated in normal plasma (NP) and in plasma of patients (n=23 each) on stable therapy with phenprocoumon (OACP). Individual line characteristics were tested statistically. RESULTS: Control ECT in OACP was prolonged compared to NP (50.1+/-0.9 vs. 45.7+/-0.8 s; p<0.001). Lepirudin prolonged the ECT linearly. Argatroban and melagatran delivered biphasic dose-response curves. OA showed additive effects on the ECT of lepirudin but not of argatroban and melagatran. Both in NP and OACP, the first and second slopes of melagatran were steeper compared to argatroban (primary analysis; p<0.001). When using the same drug, slopes in OACP were steeper than in NP (secondary analysis; p<0.001). At similar molarconcentrations, the crossing points of both slopes were significantly higher with melagatran (323.1+/-11.0 s in NP and 333.2+/-8.2 s in OACP) than with argatroban (219.6+/-14.7 and 248.4+/-15.2 s) corresponding to ratios of 7.1+/-0.2 and 6.7+/-0.2 (melagatran) vs. 4.8+/-0.3 and 4.9+/-03 with argatroban (p<0.0001). DISCUSSION: The patterns of interactions between vitamin K antagonists and DTI effects are different for bivalent (increase of slope without affecting linearity) and monovalent inhibitors (slight increase or alteration of nonlinear slopes), but there are also differences between the two monovalent inhibitors on thrombin inhibition as determined by ECT.
机译:简介:直接凝血酶抑制剂(DTI)延长了依卡琳凝血时间(ECT)。口服抗凝剂(OA)会降低凝血酶原水平,因此在伴随治疗期间会与DTI在ECT方法上的作用相互作用。材料与方法:研究了在正常血浆(NP)和患者血浆中(n = 23)苯丙香酚(OACP)稳定治疗的情况下,来普来汀,阿加曲班和美拉加群对ECT的作用。个别线特征进行了统计测试。结果:与NP相比,OACP中的对照ECT延长(50.1 +/- 0.9与45.7 +/- 0.8 s; p <0.001)。 Lepirudin线性延长ECT。 Argatroban和melagatran传递了双相剂量反应曲线。 OA显示出对Lepirudin的ECT有累加作用,但对Argatroban和Melagatran却没有影响。在NP和OACP中,与阿加曲班相比,美拉加群的第一个和第二个斜率都更陡(初步分析; p <0.001)。当使用相同的药物时,OACP的斜率比NP的斜率陡(二次分析; p <0.001)。在相似的摩尔浓度下,美加仑(NP为323.1 +/- 11.0 s,OACP为333.2 +/- 8.2 s)的两个斜率的交点都明显高于阿加曲班(219.6 +/- 14.7和248.4 +/- 15.2 s) )对应于7.1 +/- 0.2和6.7 +/- 0.2(melagatran)的比率,而使用argatroban的比率为4.8 +/- 0.3和4.9 +/- 03(p <0.0001)。讨论:维生素K拮抗剂与DTI效应之间的相互作用方式在二价(斜率增加而不会影响线性)和单价抑制剂(非线性斜率的轻微增加或改变)方面有所不同,但两种单价抑制剂对凝血酶的作用也存在差异由ECT确定的抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号